Enteromedics to start new trial of weight loss device
This article was originally published in Clinica
Executive Summary
EnteroMedics will need to carry out a new clinical trial of its troubled neuroblocking weight loss therapy, Maestro, in order to file a premarket approval (PMA) application, the US FDA has ruled.